
In this study, the role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a biomarker for atherosclerosis in patients with type 2 diabetes mellitus (T2DM) was investigated. Analyzing data from 2984 T2DM patients who underwent selective coronary angiography, elevated PCSK9 levels were found to be significantly associated with coronary heart disease (CHD) severity. Furthermore, increased circulating PCSK9 levels independently correlated with a higher risk of major cardiovascular events (MACEs) during a six-year follow-up. The findings emphasize the potential of PCSK9 as a valuable indicator of CHD progression and cardiovascular risk in T2DM patie
Like
Save
Share